Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Unichem Laboratories's EV-to-EBIT or its related term are showing as below:
NSE:UNICHEMLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -965.19 Med: -22.43 Max: 269.14
Current: 12.37
During the past 13 years, the highest EV-to-EBIT of Unichem Laboratories was 269.14. The lowest was -965.19. And the median was -22.43.
NSE:UNICHEMLAB's EV-to-EBIT is ranked better than 60.87% of 690
companies
in the Drug Manufacturers industry
Industry Median: 15.46
vs NSE:UNICHEMLAB: 12.37
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Unichem Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹22,767 Mil.
Unichem Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,240 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unichem Laboratories EV-to-EBIT Related Terms
Unichem Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Unichem Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:UNICHEMLAB vs ZTS, UTHR: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unichem Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Unichem Laboratories's EV-to-EBIT falls into.
Unichem Laboratories's current Enterprise Value is ₹40,073 Mil.
Unichem Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,240 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unichem Laboratories (NSE:UNICHEMLAB) has a EV-to-EBIT of 12.37 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Unichem Laboratories and its competitors. According to the industry distribution chart, Unichem Laboratories ranks #270 out of 690 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Unichem Laboratories' EV-to-EBIT too high?
Unichem Laboratories' current EV-to-EBIT is 12.37. The Drug Manufacturers industry median EV-to-EBIT is 15.46. Unichem Laboratories' value of 12.37 is 20% below this industry median. Based on the distribution chart, Unichem Laboratories ranks #270 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Unichem Laboratories has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unichem Laboratories ranks #270 out of 690 companies for EV-to-EBIT. This puts Unichem Laboratories in the upper half of its industry. The industry median EV-to-EBIT is 15.46. Unichem Laboratories' value of 12.37 is 20% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unichem Laboratories's current EV-to-EBIT of 12.37 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Unichem Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unichem Laboratories's current EV-to-EBIT is 12.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹681.37, compared to a current price of ₹537.35 — trading 21.1% below its estimated fair value. The current EV-to-EBIT is 12.37 and 20% below the Drug Manufacturers industry median of 15.46. Unichem Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current EV-to-EBIT is 12.37 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued.
The current stock price of ₹537.35 is trading 21.1% below its estimated GF Value™ of ₹681.37.
GuruFocus considers Unichem Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:UNICHEMLAB:
EV-to-EBIT: 12.37
GF Value™: ₹681.37 vs. price of ₹537.35 (21.1% below fair value)
Industry Position: 20% below the Drug Manufacturers median (#270 of 690)
No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
75GF Score
Get the complete analysis for NSE:UNICHEMLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:UNICHEMLAB has been successfully added to your 
